Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
HTG MOLECULAR DIAGNOSTICS, INC (HTGM)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Mar-31-23 | Mar-05-23 | Jun-30-22 | Mar-31-22 | Mar-05-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 8-K | 10-Q | 10-Q | 8-K | 10-K | 10-Q | 10-Q |
| Total revenues | 1.0 | -0.1 | 1.5 | 1.2 | 0.3 | 2.9 | 2.5 | 2.1 |
| Revenue growth | -12.8% | -135.5% | -28.1% | -17.5% | | 11.4% | 41.8% | 5.6% |
| Cost of goods sold | 1.1 | 0.0 | 1.0 | 0.9 | 0.0 | 1.4 | 1.0 | 1.0 |
| Gross profit | -0.1 | -0.1 | 0.5 | 0.3 | 0.3 | 1.5 | 1.5 | 1.1 |
| Gross margin | -11.3% | 100.0% | 32.0% | 27.8% | 100.0% | 52.9% | 61.0% | 53.2% |
| Selling, general and administrative [+] | 4.9 | 3.3 | 6.2 | 6.6 | 4.7 | 4.6 | 4.2 | 5.2 |
| General and administrative | | | | | | 4.6 | | |
| Research and development | | 1.6 | | | 1.9 | 1.9 | 1.5 | |
| Other operating expenses | 0.1 | | 0.4 | 0.5 | | | | -3.0 |
| EBITDA [+] | -5.0 | | -5.9 | -6.6 | | -4.8 | -4.0 | -0.9 |
| EBITDA growth | -23.6% | -19.9% | 531.4% | 49.5% | | 28.5% | -16.4% | -79.8% |
| EBITDA margin | -484.9% | 4280.7% | -397.0% | -553.4% | -1898.6% | -166.0% | -160.2% | -45.2% |
| Depreciation and amortization | 0.1 | | 0.2 | 0.2 | | 0.2 | 0.2 | 0.2 |
| EBIT [+] | -5.1 | -5.0 | -6.1 | -6.7 | -6.3 | -4.9 | -4.2 | -1.1 |
| EBIT growth | -24.4% | -19.9% | 446.0% | 47.1% | | 22.5% | -18.2% | -77.7% |
| EBIT margin | -493.2% | 4280.7% | -408.3% | -569.1% | -1898.6% | -171.3% | -167.8% | -53.8% |
| Interest expense, net [+] | -0.1 | | 0.0 | 0.0 | | 0.3 | 0.3 | 0.0 |
| Interest expense | 0.1 | | 0.2 | 0.2 | | 0.3 | 0.3 | 0.3 |
| Interest income | 0.1 | | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 |
| Other income (expense), net | 0.1 | 5.0 | 0.4 | 0.5 | 6.3 | | | -1.2 |
| Pre-tax income | -5.1 | 0.0 | -5.9 | -6.5 | 0.0 | -5.2 | -4.5 | -2.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | | | | |
| Net income | -5.1 | 0.0 | -5.9 | -6.5 | 0.0 | -5.2 | -4.5 | -2.6 |
| Net margin | -489.6% | 0.0% | -394.8% | -548.6% | 0.0% | -180.4% | -178.2% | -126.1% |
| |
| Basic EPS [+] | ($2.28) | $0.00 | ($0.54) | ($9.73) | $0.00 | ($0.75) | ($0.60) | ($0.39) |
| Growth | -76.5% | | 36.9% | 1112.6% | | -19.3% | -46.2% | -70.0% |
| Diluted EPS [+] | ($2.28) | $0.00 | ($0.54) | ($9.73) | $0.00 | ($0.75) | ($0.60) | ($0.39) |
| Growth | -76.5% | | 36.9% | 1112.6% | | -19.3% | -46.2% | -70.0% |
| |
| Shares outstanding (basic) [+] | 2.2 | 2.2 | 11.0 | 0.7 | 0.7 | 6.9 | 7.4 | 6.7 |
| Growth | 231.6% | 231.6% | 64.5% | -88.9% | | 49.9% | 54.3% | 52.5% |
| Shares outstanding (diluted) [+] | 2.2 | 2.2 | 11.0 | 0.7 | 0.7 | 6.9 | 7.4 | 6.7 |
| Growth | 231.6% | 231.6% | 64.5% | -88.9% | | 49.9% | 54.3% | 52.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|